Subjects -> MEDICAL SCIENCES (Total: 8196 journals)
    - ANAESTHESIOLOGY (105 journals)
    - CARDIOVASCULAR DISEASES (334 journals)
    - DENTISTRY (266 journals)
    - ENDOCRINOLOGY (149 journals)
    - FORENSIC SCIENCES (43 journals)
    - HEMATOLOGY (160 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2241 journals)
    - NURSES AND NURSING (331 journals)
    - OBSTETRICS AND GYNECOLOGY (199 journals)
    - ONCOLOGY (355 journals)
    - OTORHINOLARYNGOLOGY (76 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (254 journals)
    - PSYCHIATRY AND NEUROLOGY (800 journals)
    - RESPIRATORY DISEASES (109 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (77 journals)
    - SURGERY (388 journals)

RHEUMATOLOGY (76 journals)

Showing 1 - 76 of 76 Journals sorted alphabetically
ACR Open Rheumatology     Open Access   (Followers: 5)
Advances in Rheumatology     Open Access   (Followers: 3)
African Journal of Rheumatology     Full-text available via subscription  
Aktuelle Rheumatologie     Hybrid Journal   (Followers: 2)
Annals of Rheumatology and Autoimmunity     Open Access   (Followers: 3)
Annals of the Rheumatic Diseases     Hybrid Journal   (Followers: 34)
Archives of Osteoporosis     Hybrid Journal   (Followers: 1)
Arthritis & Rheumatology     Hybrid Journal   (Followers: 64)
Arthritis Care & Research     Hybrid Journal   (Followers: 37)
Arthritis Research & Therapy     Open Access   (Followers: 14)
Australasian Musculoskeletal Medicine     Full-text available via subscription   (Followers: 5)
Best Practice & Research Clinical Rheumatology     Hybrid Journal   (Followers: 17)
BMC Musculoskeletal Disorders     Open Access   (Followers: 29)
BMC Rheumatology     Open Access   (Followers: 4)
Case Reports in Rheumatology     Open Access   (Followers: 10)
Clinical and Experimental Rheumatology     Full-text available via subscription   (Followers: 3)
Clinical Medicine Insights : Arthritis and Musculoskeletal Disorders     Open Access   (Followers: 3)
Clinical Rheumatology     Hybrid Journal   (Followers: 21)
Current Opinion in Rheumatology     Hybrid Journal   (Followers: 13)
Current Reviews in Musculoskeletal Medicine     Open Access   (Followers: 13)
Current Rheumatology Reports     Hybrid Journal   (Followers: 3)
Current Rheumatology Reviews     Hybrid Journal   (Followers: 4)
Current Treatment Options in Rheumatology     Hybrid Journal  
Egyptian Rheumatologist     Open Access   (Followers: 1)
Egyptian Rheumatology and Rehabilitation     Open Access   (Followers: 2)
Forum Reumatologiczne     Hybrid Journal  
Future Rheumatology     Full-text available via subscription   (Followers: 1)
Gait & Posture     Hybrid Journal   (Followers: 17)
Indian Journal of Rheumatology     Open Access   (Followers: 1)
Indonesian Journal of Rheumatology     Open Access  
International Journal of Clinical Rheumatology     Open Access   (Followers: 4)
International Journal of Rheumatic Diseases     Hybrid Journal   (Followers: 2)
International Journal of Rheumatology     Open Access   (Followers: 6)
International Musculoskeletal Medicine     Hybrid Journal   (Followers: 7)
Internet Journal of Rheumatology and Clinical Immunology     Open Access   (Followers: 4)
JCR Journal of Clinical Rheumatology     Hybrid Journal   (Followers: 7)
Journal of Musculoskeletal Research     Hybrid Journal   (Followers: 9)
Journal of Orthopedics & Rheumatology     Open Access  
Journal of Rheumatology     Open Access   (Followers: 32)
Modern Rheumatology     Hybrid Journal   (Followers: 4)
Modern Rheumatology Case Reports     Hybrid Journal  
Multiple Sclerosis and Related Disorders     Hybrid Journal   (Followers: 8)
Musculoskeletal Care     Hybrid Journal   (Followers: 19)
MYOPAIN. A journal of myofascial pain and fibromyalgia     Hybrid Journal   (Followers: 16)
Nature Reviews Rheumatology     Full-text available via subscription   (Followers: 25)
OA Arthritis     Open Access   (Followers: 1)
OA Inflammation     Open Access  
Open Access Rheumatology: Research and Reviews     Open Access   (Followers: 3)
Open Journal of Orthopedics and Rheumatology     Open Access  
Open Journal of Rheumatology and Autoimmune Diseases     Open Access   (Followers: 4)
Open Rheumatology Journal     Open Access  
Orthopädie & Rheuma     Full-text available via subscription  
Osteoarthritis and Cartilage     Full-text available via subscription   (Followers: 20)
Osteoarthritis and Cartilage Open     Open Access  
Osteologie     Hybrid Journal  
Osteoporosis and Sarcopenia     Open Access  
Pain. Joints. Spine     Open Access   (Followers: 1)
Reumatismo     Open Access  
Reumatología Clínica (English Edition)     Full-text available via subscription  
Revista Argentina de Reumatología     Open Access  
Revista Colombiana de Reumatologia     Open Access  
Revista Colombiana de Reumatología (English Edition)     Hybrid Journal  
rheuma plus     Hybrid Journal  
Rheumatic Disease Clinics of North America     Full-text available via subscription   (Followers: 4)
Rheumatica Acta: Open Access     Open Access  
Rheumatology     Hybrid Journal   (Followers: 33)
Rheumatology & Autoimmunity     Open Access   (Followers: 3)
Rheumatology Advances in Practice     Open Access   (Followers: 1)
Rheumatology and Therapy     Open Access   (Followers: 3)
Rheumatology International     Hybrid Journal   (Followers: 3)
Rheumatology Practice and Research     Open Access  
RMD Open     Open Access   (Followers: 1)
Scandinavian Journal of Rheumatology     Hybrid Journal   (Followers: 5)
Seminars in Arthritis and Rheumatism     Hybrid Journal   (Followers: 8)
The Lancet Rheumatology     Hybrid Journal  
Zeitschrift fur Rheumatologie     Hybrid Journal   (Followers: 6)
Similar Journals
Journal Cover
Journal of Rheumatology
Journal Prestige (SJR): 2.157
Citation Impact (citeScore): 3
Number of Followers: 32  

  This is an Open Access Journal Open Access journal
ISSN (Print) 0315-162X - ISSN (Online) 1499-2752
Published by Journal of Rheumatology Publishing Company Ltd Homepage  [1 journal]
  • Spondyloarthritis Among Patients With Uveitis: Can We Improve Referral

    • Authors: Eder; L.
      Pages: 659 - 660
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220263
      Issue No: Vol. 49, No. 7 (2022)
  • Uveitis in Juvenile Psoriatic Arthritis: Still So Much To Learn

    • Authors: Mireskandari; K.
      Pages: 661 - 662
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220163
      Issue No: Vol. 49, No. 7 (2022)
  • Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis:
           A Systematic Review and Metaanalysis

    • Authors: Hadwen, B; Yu, R, Cairns, E, Barra, L.
      Pages: 663 - 671
      Abstract: Objective.Rheumatoid arthritis (RA) is more common in females, and although the cause of RA is unknown, it is characterized by the production of autoantibodies. The aims of this study were to determine whether RA-associated autoantibodies are more often found in females than males and to identify factors that influence the relationship between sex and seropositivity.Methods.Databases were searched and studies of RA (N ≥ 100) were included if they reported proportion of seropositive patients with RA by sex. Metaanalyses and metaregression were conducted using the random-effects model. Covariates regressed were smoking, age, BMI, Health Assessment Questionnaire–Disability Index (HAQ-DI), and the Disease Activity Score in 28 joints (DAS28).Results.Eighty-four studies with a total of 141,381 subjects with rheumatoid factor (RF) seropositivity and 95,749 subjects with anticitrullinated protein antibody (ACPA) seropositivity met inclusion criteria. The mean age of participants ranged from 37 to 68 years and the proportion of female subjects ranged from 9% to 92%. Results indicated that females were less likely than males to be seropositive: odds ratio (OR) 0.84 [95% CI 0.77–0.91] for RF and OR 0.88 [95% CI 0.81–0.95] for ACPA. BMI, smoking, mean age, DAS28, and HAQ-DI did not affect the relationship between sex and seropositivity.Conclusion.Although studies report that females have higher RA disease activity than males and that seropositivity predicts worse outcomes, females were less likely to be seropositive than males.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211020
      Issue No: Vol. 49, No. 7 (2022)
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid
           Arthritis (RA)-associated Bronchiectasis: Role of RA-related

    • Authors: McDermott, G; Gill, R, Gagne, S, Byrne, S, Huang, W, Wang, X, Prisco, L. C, Zaccardelli, A, Martin, L. W, Masto, L, Kronzer, V. L, Shadick, N, Dellaripa, P. F, Doyle, T. J, Sparks, J. A.
      Pages: 672 - 679
      Abstract: Objective.To investigate demographic, lifestyle, and serologic risk factors for isolated rheumatoid arthritis (RA)–associated bronchiectasis (RA-BR) that is not a result of interstitial lung disease (ILD).Methods.We performed a case-control study using patients with RA from the Mass General Brigham Biobank. We reviewed the records of all patients with RA meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria with computed tomography (CT) chest imaging to identify RA-BR cases and controls with RA and RA-related lung disease. For each patient, the CT chest imaging that was performed closest to enrollment was independently reviewed by 2 radiologists for the presence of RA-related lung diseases. Cases had clinical and radiologic evidence of RA-BR without interstitial lung abnormalities on imaging. Controls had RA and no evidence of bronchiectasis or ILD. We examined the associations between demographic, lifestyle, and serologic factors with RA-BR using multivariable logistic regression.Results.We identified 57 cases of isolated RA-BR and 360 RA controls without RA-related lung disease. In multivariable models, RA-BR was associated with older age at RA onset (OR 1.37 per 10 years, 95% CI 1.02–1.82), lower BMI at RA diagnosis (OR 0.94 per kg/m2, 95% CI 0.89–0.99), seropositive RA (OR 3.96, 95% CI 1.84–8.53), positive rheumatoid factor (OR 4.40, 95% CI 2.14–9.07), and positive anticyclic citrullinated peptide (OR 3.47, 95% CI 1.65–7.31). Higher titers of RA-related autoantibodies were associated with higher odds of RA-BR.Conclusion.Seropositivity, older age at RA diagnosis, and lower BMI at RA onset were associated with isolated bronchiectasis in RA that was not a result of ILD. These findings expand the list of potential risk factors for RA-BR and suggest a pathogenic link between airway inflammation and RA-related autoantibodies.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211242
      Issue No: Vol. 49, No. 7 (2022)
  • High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in
           Patients Referred With Anterior Uveitis and Chronic Back Pain: The SpEYE

    • Authors: van Bentum, R. E; Verbraak, F. D, Wolf, S, Ongkosuwito, J, Boers, M, Tan, H. S, van der Horst-Bruinsma, I. E.
      Pages: 680 - 687
      Abstract: Objective.To reduce the diagnostic delay in axial spondyloarthritis (axSpA), guidelines recommend referring patients with acute anterior uveitis (AAU) and chronic back pain (CBP) to a rheumatologist. This observational study in daily practice evaluated the prevalence of previously unrecognized axSpA in patients with AAU who were referred by ophthalmologists because of concurrent CBP.Methods.All patients with AAU referred with CBP (≥ 3 months, age of onset < 45 yrs) from 5 ophthalmology clinics underwent rheumatologic assessment, including pelvic radiographs. Patients with previously diagnosed rheumatic disease and AAU due to other causes were excluded. The primary endpoint was a clinical axSpA diagnosis by the rheumatologist.Results.Eighty-one patients fulfilled the referral criteria (52% male, 56% HLA-B27 positive, median age 41 yrs, median CBP duration 10 yrs). In total, 58% (n = 47) had recurring AAU, of whom 87% already had CBP during previous AAU attacks. After assessment, 23% (n = 19) of patients were clinically diagnosed with definite axSpA (10/19 radiographic), 40% (n = 32) with suspicion of axSpA, and 37% (n = 30) with no axSpA. AxSpA was diagnosed more often in men (33% of the men vs 13% of the women).Conclusion.A high prevalence of axSpA was found in patients with AAU referred because of CBP. There was substantial diagnostic delay in the majority of patients with recurring AAU, as many already had CBP during previous AAU flares. In AAU, screening for CBP and prompt referral has a high diagnostic yield and should consistently be promoted among ophthalmologists.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210345
      Issue No: Vol. 49, No. 7 (2022)
  • Mortality Rates in Patients With Ankylosing Spondylitis With and Without
           Extraarticular Manifestations and Comorbidities: A Retrospective Cohort

    • Authors: Kelty, E; Ognjenovic, M, Raymond, W. D, Inderjeeth, C. A, Keen, H. I, Preen, D. B, Nossent, J. C.
      Pages: 688 - 693
      Abstract: Objective.To examine mortality rates in hospitalized patients with ankylosing spondylitis (AS) and the association of extraarticular manifestations (EAMs) and comorbidities with mortality rates.Methods.This study was a retrospective, population-based cohort study using linked administrative data from patients with AS who were hospitalized (n = 1791) and patients in a matched comparison group (n = 8955). Mortality data for patients were obtained from the Western Australia Death Register. The presence of EAMs and comorbidities was identified from hospital records. Mortality rates were compared between the 2 groups using Cox proportional hazard models overall and stratified by a history of EAMs, comorbidities, and smoking status.Results.Crude mortality rates were significantly higher among patients with AS than among patients in the comparison group (hazard ratio [HR] 1.85, 95% CI 1.62–2.12), with excess mortality in the AS group associated with cardiovascular disease (CVD; HR 5.32, 95% CI 3.84–7.35), cancer (HR 1.68, 95% CI 1.27–2.23), external causes (HR 3.92, 95% CI 2.28–6.77), and infectious diseases (HR 25.92, 95% CI 7.50–89.56). When patients were stratified by history of EAMs, CVD, and smoking, the risk of mortality was elevated in patients both with and without each risk factor. Among patients with AS, histories of CVD (HR 6.33, 95% CI 4.79–8.38), diabetes (HR 2.81, 95% CI 1.99–3.95), smoking (HR 1.49, 95% CI 1.18–1.89), and EAMs (HR 1.62, 95% CI 1.24–2.11) were associated with an increased risk of mortality.Conclusion.The presence of comorbidities, EAMs, and smoking contributes to an increased risk of all-cause mortality among patients with AS who are hospitalized compared to patients in the comparison group. These results support the need to prevent or reduce the occurrence of comorbidities and smoking in patients with AS.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210909
      Issue No: Vol. 49, No. 7 (2022)
  • Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets
           With Apremilast: Phase III Results in DMARD-naïve Patients With
           Psoriatic Arthritis

    • Authors: Mease, P. J; Kavanaugh, A, Ogdie, A, Wells, A. F, Bergman, M, Gladman, D. D, Richter, S, Teng, L, Jardon, S, Smolen, J. S.
      Pages: 694 - 699
      Abstract: Objective.The probability of achieving Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) treatment targets (remission [REM], low disease activity [LDA]) was evaluated following apremilast monotherapy in disease-modifying antirheumatic drug (DMARD)-naïve patients with psoriatic arthritis (PsA) based on baseline disease activity.Methods.This post hoc probability analysis of PALACE 4, a phase III, multicenter, randomized, placebo-controlled study, evaluated shifting across cDAPSA categories from baseline to week 52 and included DMARD-naïve patients receiving apremilast 30 mg BID with available baseline cDAPSA data. Changes in articular/extraarticular manifestations were evaluated in patients with week 52 cDAPSA components. cDAPSA treatment target achievement was assessed in a subgroup with baseline extraarticular PsA manifestations (skin involvement, enthesitis, dactylitis).Results.Of 175 apremilast-treated patients in the probability analysis, 66.3% were in high disease activity (HDA) and 31.4% in moderate disease activity (ModDA) at baseline. Approximately twice as many patients in ModDA at baseline reached REM/LDA at week 52 vs those in HDA (61.7% vs 28.2%). Achieving cDAPSA treatment targets was associated with reductions in articular (swollen/tender joints) and extraarticular (skin involvement, enthesitis, dactylitis, functional disability) disease activity. Similar treatment target achievement rates were observed in the subgroup with ≥ 1 extraarticular PsA manifestation (n = 126; ModDA: 66.7%, HDA: 32.2%).Conclusion.Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. Resolution and/or near resolution of articular and/or extraarticular PsA manifestations was achieved by patients in REM/LDA at week 52. Consistent treatment target achievement was observed in patients with 1 or multiple extraarticular manifestations of active PsA.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210906
      Issue No: Vol. 49, No. 7 (2022)
  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic

    • Authors: Mease, P. J; Blachley, T, Dube, B, McLean, R. R, Kim, N, Hur, P, Ogdie, A.
      Pages: 700 - 706
      Abstract: Objective.To evaluate clinical and patient-reported outcomes (PROs) at 6 months after secukinumab initiation in US patients with psoriatic arthritis (PsA).Methods.Patients with PsA in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry who initiated secukinumab between April 1, 2017, and December 2, 2019, and maintained secukinumab at their 6-month follow-up visit were included. Achievement of minimal disease activity (MDA) among patients not in MDA at initiation; resolution (ie, no evidence) of tender and swollen joint counts, enthesitis, and dactylitis among patients with ≥ 1 of these at initiation; and change in disease activity and PROs were evaluated at 6 months in all patients and in patients who received secukinumab as a first-line biologic.Results.Of the 100 eligible patients included, most (83.0%) were biologic experienced and 17.0% initiated secukinumab as a first-line biologic. At initiation, 75/90 patients (83.3%) with available data were not in MDA; 26/71 (36.6%) with follow-up data achieved MDA at 6 months. Further, 28/68 patients (41.2%) with ≥ 1 tender joint, 24/54 (44.4%) with ≥ 1 swollen joint, 17/28 (60.7%) with enthesitis, and 9/12 (75.0%) with dactylitis at initiation achieved resolution at 6 months. Improvements in clinical manifestations, PRO measures, and work productivity and activity were observed after 6 months among patients with PsA who initiated and maintained secukinumab.Conclusion.In this real-world population, patients with PsA who received and maintained secukinumab for 6 months achieved MDA in proportions consistent with clinical trials and demonstrated improvements in clinical manifestations and PROs.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211033
      Issue No: Vol. 49, No. 7 (2022)
  • Tacrolimus in Patients With Interstitial Pneumonia Associated With
           Polymyositis or Dermatomyositis: Interim Report of Postmarketing
           Surveillance in Japan

    • Authors: Kuwana, M; Wakasugi, N, Furuya, T, Uno, S, Suda, T.
      Pages: 707 - 718
      Abstract: Objective.The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia (IP) in patients with polymyositis (PM) and dermatomyositis (DM). Postmarketing surveillance was initiated to examine long-term outcomes of immunosuppressive regimens containing tacrolimus in real-world settings.Methods.Observational, prospective, postmarketing surveillance is ongoing in 179 patients with PM/DM-associated IP initiating treatment with tacrolimus. We report interim findings after 2 years of follow-up. Cumulative overall survival was assessed using Kaplan-Meier analysis. Potential prognostic factors for mortality were assessed by univariate Cox proportional hazards analysis.Results.A total of 170 patients were included in this analysis. At the time of starting treatment with tacrolimus, almost all patients were receiving corticosteroids (98.8%), and cyclophosphamide was additionally used in 42 patients (24.7%). Forty-nine patients (28.8%) discontinued tacrolimus during follow-up, mainly due to loss to follow-up, patient death, and adverse events. Mean (SD) oral corticosteroid dose decreased from 32.4 (21.6) mg/day at baseline to 7.6 (4.2) mg/day at 2 years. Overall survival at 2 years was 90.3%; corresponding progression-free survival was 62.5%. Factors found to be associated with all-cause mortality included diagnosis of clinically amyopathic DM (hazard ratio [HR] 9.04, 95% CI 1.18-69.51 vs PM), ferritin level 500 to < 1500 ng/mL (HR 8.61, 95% CI 2.51-29.45 vs < 500 ng/mL), and presence of antimelanoma differentiation-associated gene 5 antibodies (HR 8.16, 95% CI 1.03–64.47 vs absence).Conclusion.Immunosuppressive regimens containing tacrolimus appear useful for the management of IP in patients with PM/DM. [ NCT02159651]
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210322
      Issue No: Vol. 49, No. 7 (2022)
  • Occurrence and Risk Factors of Uveitis in Juvenile Psoriatic Arthritis:
           Data From a Population-based Nationwide Study in Germany

    • Authors: Baquet-Walscheid, K; Rothaus, K, Niewerth, M, Klotsche, J, Minden, K, Heiligenhaus, A.
      Pages: 719 - 724
      Abstract: Objective.Data on uveitis in juvenile psoriatic arthritis (JPsA), a category of juvenile idiopathic arthritis (JIA), are scarce. We describe prevalence and risk factors for JPsA-associated uveitis (JPsA-U).Methods.Cross-sectional data from the German National Pediatric Rheumatological Database (2002–2014) were used to characterize JPsA-U and assess risk factors for the development of uveitis.Results.Uveitis developed in 6.6% of 1862 patients with JPsA. Patients with JPsA-U were more frequently female (73.0 vs 62.9%, P = 0.03), antinuclear antibody (ANA) positive (60.3 vs 37.0%, P < 0.001), younger at JPsA onset (5.3 ± 4.1 vs 9.3 ± 4.4 yrs, P < 0.001), and treated with disease-modifying antirheumatic drugs (DMARDs) significantly more frequently compared with JPsA patients without uveitis. On a multivariable analysis of a subgroup of 655 patients enrolled in the study ≤ 1 year after arthritis onset, mean clinical Juvenile Arthritis Disease Activity Score for 10 joints during study documentation was significantly associated with uveitis development. Children with early onset of JPsA (aged < 5 yrs vs ≥ 5 yrs) were significantly more frequently ANA positive (48.4% vs 35.7%, P < 0.001), affected by uveitis (17.3% vs 3.8%, P < 0.001), and treated with DMARDs (52.9% vs 43.8%, P < 0.001), but less often affected by skin disease (55.3% vs 61.0%, P = 0.03).Conclusion.The characteristics of patients with JPsA developing uveitis are similar to those of patients with uveitis in other JIA categories, such as oligoarticular JIA. Children with early-onset JPsA are at a higher risk for ocular involvement. Our data support the notion of a major clinical difference between those patients with early vs late onset of JPsA.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210755
      Issue No: Vol. 49, No. 7 (2022)
  • Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and
           Identifying Predictors of Admission

    • Authors: Russell, M. D; Nagra, D, Clarke, B. D, Balachandran, S, Buazon, A, Boalch, A, Bechman, K, Adas, M. A, Alveyn, E. G, Rutherford, A. I, Galloway, J. B.
      Pages: 725 - 730
      Abstract: Objective.To identify predictors of admission following emergency department (ED) attendances for gout flares and to describe barriers to optimal inpatient gout care.Methods.ED attendances and hospital admissions with primary diagnoses of gout were analyzed at 2 UK-based hospitals between January 1, 2017, and December 31, 2020. Demographic and clinical predictors of ED disposition (admission or discharge) and reattendance for gout flares were identified using logistic regression and survival models, respectively. Case note reviews (n = 59), stakeholder meetings, and process mapping were performed to capture detailed information on gout management and to identify strategies to optimize care.Results.Of 1220 emergency attendances for gout flares, 23.5% required hospitalization (median length of stay: 3.6 days). Recurrent attendances for flares occurred in 10.4% of patients during the study period. In multivariate logistic regression models, significant predictors of admission from ED were older age, overnight ED arrival time, higher serum urate (SU), higher C-reactive protein, and higher total white cell count at presentation. Detailed case note reviews showed that only 22.6% of patients with preexisting gout were receiving urate-lowering therapy (ULT) at presentation. Initial diagnostic uncertainty was common, yet rheumatology input and synovial aspirates were rarely obtained. By 6 months postdischarge, 43.6% were receiving ULT; however, few patients had treat-to-target dose optimization, and only 9.1% achieved SU levels ≤ 360 μmol/L.Conclusion.We identified multiple predictors of hospitalization for acute gout. Treat-to-target optimization of ULT following hospitalization remains inadequate and must be improved if admissions are to be prevented.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211203
      Issue No: Vol. 49, No. 7 (2022)
  • Gout and Hospital Admission for Ambulatory Care-Sensitive Conditions:
           Risks and Trajectories

    • Authors: Kiadaliri, A; Neogi, T, Englund, M.
      Pages: 731 - 739
      Abstract: Objective.To investigate the risks and trajectories of hospital admission for ambulatory care–sensitive conditions (ACSCs) in gout.Methods.Among individuals aged 35 years to 85 years residing in Skåne, Sweden, in 2005, those with no doctor-diagnosed gout during 1998 to 2005 (n = 576,659) were followed from January 1, 2006, until a hospital admission for an ACSC, death, relocation outside Skåne, or December 31, 2016. Treating a new gout diagnosis (International Classification of Diseases, 10th revision, code M10) as a time-varying exposure, we used Cox proportional and additive hazard models to estimate the effects of gout on hospital admissions for ACSCs. We investigated the trajectory of hospital admissions for ACSCs from 3 years before to 3 years after gout diagnosis using generalized estimating equations and group-based trajectory modeling in an age-and sex-matched cohort study.Results.Gout was associated with a 41% increased rate of hospital admission for ACSCs (hazard ratio 1.41, 95% CI 1.35-1.47), corresponding to 121 (95% CI 104-138) more hospital admissions for ACSCs per 10,000 person-years compared with those without gout. Our trajectory analysis showed that higher rates of hospital admission for ACSCs among persons with gout were observed from 3 years before to 3 years after diagnosis, with the highest prevalence rate ratio (2.22, 95% CI 1.92-2.53) at the 3-month period after diagnosis. We identified 3 classes with distinct trajectories of hospital admissions for ACSCs among patients with gout: almost none (88.5%), low-rising (9.7%), and moderate-sharply rising (1.8%). The Charlson Comorbidity Index was the most important predictor of trajectory class membership.Conclusion.Increased risk of hospital admissions for ACSCs in gout highlights the need for better management of the disease through outpatient care, especially among foreign-born, older patients with comorbidities.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220038
      Issue No: Vol. 49, No. 7 (2022)
  • Healthcare Utilization and Costs for Musculoskeletal Disorders in Ontario,

    • Authors: Power, J. D; Perruccio, A. V, Paterson, J. M, Canizares, M, Veillette, C, Coyte, P. C, Badley, E. M, Mahomed, N. N, Rampersaud, Y. R.
      Pages: 740 - 747
      Abstract: Objective.To examine the magnitude and costs of ambulatory primary care, specialist physician care, and hospital service use for musculoskeletal disorders (MSDs) in Canada’s largest province, Ontario.Methods.Administrative health databases were analyzed for fiscal year 2013–2014 for adults aged ≥ 18 years, including data on physician services, emergency department (ED) visits, and hospitalizations. International Classification of Diseases diagnostic codes were used to identify MSD services. A validated algorithm was used to estimate direct medical costs. Person-visit rates and numbers of persons and visits were tabulated by care setting, age, sex, and physician specialty. Data were examined for all MSDs combined, as well as for specific diagnostic groupings.Results.Overall, 3.1 million adult Ontarians (28.5%) made over 8 million outpatient physician visits associated with MSDs. These included 5.6 million primary care visits. MSDs accounted for 560,000 (12.3%) of all adult ED visits. Total costs for MSD-related care were $1.6 billion, with 12.6% of costs attributed to primary care, 9.2% to specialist care, 8.6% to ED care, 8.5% to day surgery, and 61.2% associated with inpatient hospitalizations. Costs due to arthritis accounted for 40% of total MSD care costs ($639 million). MSD-related imaging costs were $169 million, yielding a total cost estimate of $1.8 billion for MSDs overall.Conclusion.MSDs place a significant and costly burden on the healthcare system. Health system planning needs to consider the large and escalating demand for care to reduce both the individual and population burden.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210938
      Issue No: Vol. 49, No. 7 (2022)
  • IgG4-related Disease With Destructive Nasal Bone Involvement Leading to
           Saddle Nose Deformity

    • Authors: Loizidis, G; Rabinowitz, M. R, Tuluc, M.
      Pages: 748 - 749
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.200621
      Issue No: Vol. 49, No. 7 (2022)
  • Canadian Rheumatology Association Annual Meeting, February 2-5, 2022

    • Authors: Canadian Rheumatology Association
      Pages: 751 - 847
      Abstract: The 76th Annual Meeting of the Canadian Rheumatology Association was held virtually on February 2–5, 2022. The program consisted of presentations covering original research, symposia, awards, and lectures. Highlights of the meeting include the following 2022 Award Winners: Distinguished Rheumatologist, John G. Hanly and Lori B. Tucker; Distinguished Teacher-Educator, Stephen Aaron; Emerging Investigator, Jessica Widdifield; Ian Watson Award for the Best on SLE Research by a Trainee, Maher Banjari; Phil Rosen Award for the Best on Clinical or Epidemiology Research by a Trainee, Molly Dushnicky; Best by a Rheumatology Resident, Wen Qi; Best on Basic Science Research by a Trainee, Omar Cruz Correa; Best by a Post-Graduate Research Trainee, Holly Philpott; Best on Quality Care Initiatives in Rheumatology, Michael Zeeman; Best by a Medical Student, Samir Magdy Iskander; Best by an Undergraduate Student, Daniel Onwuka; Best by a Rheumatology Post-Graduate Research Trainee, Jennifer Lee; Best on Research by Young Faculty, Nancy Maltez; Best on Pediatric Research by Young Faculty, Chelsea DeCoste; Best on Spondyloarthritis Research, Vanessa Ocampo; Practice Reflection Award, Gold, Bailey Dyck. Lectures and other events included: Keynote Lecture by Grace Wright: Towards Equity: Is Everyone in the Rheum Paving the Path to Equity with Diversity'; State of the Art Lecture by Tuhina Neogi: Pain Across the Spectrum of Rheumatic Diseases; Dunlop-Dottridge Lecture by Simon Carette: Vasculitis: What Have We Learned in the Past 50 Years'; and the Great Debate: Be it Resolved that the Rheumatology Healthcare Provider Is Responsible for Prescribing and Monitoring Physical Activity. Arguing for: Claire LeBlanc and Laura Passalent, and against: Arthur Bookman and Marie Clements-Baker. Topics including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjögren syndrome, psoriatic arthritis, spondyloarthritis, vasculitis, osteoarthritis, fibromyalgia, and their respective diagnoses, treatments, and outcomes are reflected in the abstracts, which we are pleased to publish in this issue of The Journal of Rheumatology.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220297
      Issue No: Vol. 49, No. 7 (2022)
  • Vasculitis: What Have We Learned in the Last 50 Years'

    • Authors: Carette; S.
      Pages: 848 - 852
      Abstract: Realizing in the fall of 2021 that I had started medical school exactly 50 years ago, on September 7, 1971, I thought that it would be interesting for the 2022 Dunlop-Dottridge Lecture to briefly review what we knew about vasculitis prior to 1971 and then reflect on what we have learned since.
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220207
      Issue No: Vol. 49, No. 7 (2022)
  • Getting the Diagnosis Right: Whats in a Name'

    • Authors: Chatterjee; S.
      Pages: 853 - 854
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.220017
      Issue No: Vol. 49, No. 7 (2022)
  • Impaired Humoral Immunogenicity of SARS-CoV-2 Vaccination in Patients With
           Rheumatoid Arthritis

    • Authors: Moine, C. L; Soyfoo, M. S, Mekkaoui, L, Dahma, H, Tant, L.
      Pages: 855 - 858
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211270
      Issue No: Vol. 49, No. 7 (2022)
  • A Case of Scleromyxedema Development Following Intravesical Bacillus
           Calmette-Guerin Administration

    • Authors: Yildirim, R; Cansu, D. U, Korkmaz, C.
      Pages: 858 - 859
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211010
      Issue No: Vol. 49, No. 7 (2022)
  • Post SARS-CoV-2 Vaccine Chilblains-like Lesions

    • Authors: Mungmunpuntipantip, R; Wiwanitkit, V.
      Pages: 859 - 859
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.210996
      Issue No: Vol. 49, No. 7 (2022)
  • Association of Sedentary Behavior and Physical Activity With Hyperuricemia
           and Sex Differences: Results From the China Multi-Ethnic Cohort Study

    • Authors: Hong, R; Huang, J, Xu, C, Zhang, X, Mi, F, Xu, F, Wang, Y, Feng, Y, Yin, J.
      Pages: 860 - 860
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211180.C1
      Issue No: Vol. 49, No. 7 (2022)
  • Dr. Trefond et al reply: Giant Cell Arteritis After SARS-CoV-2
           Vaccination--Coincidence or Trigger'

    • Authors: Trefond, L; Sauret, A, Stievenart, J, Olagne, L, Guelon, B, Smets, P, Aumaitre, O, Andre, M.
      Pages: 860 - 860
      PubDate: 2022-07-01T04:00:24-07:00
      DOI: 10.3899/jrheum.211158.C1
      Issue No: Vol. 49, No. 7 (2022)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-